Human Microbiome Market Size, Share | Report 2021, 2028

The human microbiome market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021–2028.

The human microbiota consists of the trillions of symbiotic microbial cells harbored by each person mainly bacteria in the gut. The microbes, including bacteria, fungi, and viruses, are the disease-causing agent that accumulate over time, and the habitat in gut transforms their genetic activities and metabolic processes, resulting in an abnormal immune response against the substances and tissues that normally present in the human body. Several microbiome projects have been launched worldwide with the aim to understand the roles played by these symbionts and their impact on the health of human host. The growth of the human microbiome market is attributed to the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies, and growing technological advancements in metagenomics and next-generation sequencing. However strict government guidelines and lack of knowledge about detailed examination hinders the market growth.  

Market Insights

Increasing Incidence of Lifestyle Diseases

In the past few decades, researchers have come up with the clarity on the relation between human microbiome and lifestyle diseases such as cancer, diabetes, obesity, and depression. Changes in lifestyles and societal norms influence the microbiome at each stage of life. Altering the human microbiome can help eliminate such lifestyle diseases. As per World Health Organization, 13% of the world population (adults) was obese in 2016. According to the “The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation,” published in 2016, microbes residing in the human gastrointestinal tract act as an endocrine organ whose composition and functionality contribute to the development of obesity. Therefore, fecal/gut microbiome transplantation (GMT), involving the transfer of feces from a healthy donor to the patient, is a potential treatment for obesity.

Diabetes is one of the global health emergencies of the 21st century. According to the International Diabetes Federation (IDF), the number of people suffering from diabetes in North America was ~46 million in 2017, which is expected to rise to 62 million by 2045, i.e., with the disease prevalence of ~35% during the forecast period. The reduced levels of Firmicutes Clostridia indicate the microbiome of patients with diabetes butyrate-producing bacteria and an increased ratio of Bacteroidetes: Firmicutes. Thus, diabetes can be prevented as well as treated by altering the microbiome by administration of prebiotics, probiotics, and fecal transplantation. Therefore, the increasing incidence of chronic lifestyle diseases is driving the human microbiome market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Human Microbiome Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Product-Based Insights

Based on product, the human microbiome market is segmented into foods, medical foods, probiotics, prebiotics, drugs, diagnostic devices, and supplements. The probiotics segment is projected to hold the largest market share in 2021, and the prebiotics segment is anticipated to register the highest CAGR in the market during the forecast period.

Report Coverage

Disease-Based Insights

The human microbiome market, by disease, is segmented into diabetes, cancer, autoimmune disorders, obesity, mental disorders, and other diseases. The market for the human microbiome is emerging owing to rising incidences of lifestyle diseases such as cancer and diabetes. The obesity segment is expected to hold the largest share of the market in 2021, whereas the diabetes segment is estimated to register the highest CAGR during the forecast period.

Application-Based Insights

The human microbiome market, by application, is segmented into diagnostics and therapeutics. The therapeutics segment is projected to hold a larger market share in 2021, and it is further estimated to register a higher CAGR during the forecast period.

Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios. Companies in the human microbiome market focus on the collaboration strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world.

Human Microbiome Market Regional Insights

The regional trends and factors influencing the Human Microbiome Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Human Microbiome Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Human Microbiome Market Market Report Scope

Market Players Density: Understanding Its Impact on Business Dynamics

The Human Microbiome Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Human Microbiome Market are:

1. Rebiotix Inc.
2. Yakult Honsha Co., Ltd.
3. Synthetic Biologics Inc.
4. DuPont
5. MaaT Pharma

Disclaimer: The companies listed above are not ranked in any particular order.

Human Microbiome Market – by Product

• Probiotics 
• Foods
• Prebiotics
• Medical Foods
• Diagnostic Devices
• Drugs
• Supplements

Human Microbiome Market – by Disease  

• Obesity
• Diabetes
• Autoimmune Disorders
• Cancer
• Mental Disorders
• Others

 Human Microbiome Market – by Application   

• Therapeutics
• Diagnostics

Human Microbiome Market – by Geography

• North America

  • US
  • Canada
  • Mexico

• Europe

  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe

• Asia Pacific (APAC)

  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of Asia Pacific

• Middle East and Africa (MEA)

  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa

• South and Central America (SCAM)

  • Brazil
  • Argentina
  • Rest of South and Central America

Company Profiles

• Rebiotix Inc.
• Yakult Honsha Co., Ltd.
• Synthetic Biologics Inc.
• DuPont
• MaaT Pharma
• Eligo Bioscience
• Merck & Co. Inc
• AOBiome LLC
• Kaleido
• Seres Therapeutics